Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Relay Therapeutics, Inc is a biotechnology business based in the US. Relay Therapeutics shares (RLAY) are listed on the NASDAQ and all prices are listed in US Dollars. Relay Therapeutics employs 132 staff and has a market cap (total outstanding shares value) of USD$4.9 billion.
|Latest market close||USD$49.62|
|52-week range||USD$32.56 - USD$57.59|
|50-day moving average||USD$43.2917|
|200-day moving average||USD$40.3131|
|Wall St. target price||USD$52.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.99|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||N/A|
|1 month (2020-10-27)||27.49%|
|3 months (2020-08-23)||N/A|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-23)||N/A|
|2 years (2018-11-23)||N/A|
|3 years (2017-11-23)||N/A|
|5 years (2015-11-23)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$4.9 billion|
TTM: trailing 12 months
There are currently 4.8 million Relay Therapeutics shares held short by investors – that's known as Relay Therapeutics's "short interest". This figure is 2.7% down from 5.0 million last month.
There are a few different ways that this level of interest in shorting Relay Therapeutics shares can be evaluated.
Relay Therapeutics's "short interest ratio" (SIR) is the quantity of Relay Therapeutics shares currently shorted divided by the average quantity of Relay Therapeutics shares traded daily (recently around 201015.00415628). Relay Therapeutics's SIR currently stands at 24.06. In other words for every 100,000 Relay Therapeutics shares traded daily on the market, roughly 24060 shares are currently held short.
However Relay Therapeutics's short interest can also be evaluated against the total number of Relay Therapeutics shares, or, against the total number of tradable Relay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relay Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Relay Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.106% of the tradable shares (for every 100,000 tradable Relay Therapeutics shares, roughly 106 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Relay Therapeutics.
Find out more about how you can short Relay Therapeutics stock.
We're not expecting Relay Therapeutics to pay a dividend over the next 12 months.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.